Plus Therapeutics, Inc. (NASDAQ:PSTV) went up by 30.32% from its latest closing price compared to the recent 1-year high of $16.00. The company’s stock price has collected -7.22% of loss in the last five trading sessions. Press Release reported 10 hours ago that Plus Therapeutics Receives Fast Track Designation From FDA for Its Novel Glioblastoma Treatment
Is It Worth Investing in Plus Therapeutics, Inc. (NASDAQ :PSTV) Right Now?
Plus, the 36-month beta value for PSTV is at 0.51. Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for Plus Therapeutics, Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $5.00, which is -$3.18 below the current price. PSTV currently public float of 3.98M and currently shorts hold a 6.89% ratio of that float. Today, the average trading volume of PSTV was 474.82K shares.
PSTV’s Market Performance
PSTV stocks went down by -7.22% for the week, with a monthly drop of -16.44% and a quarterly performance of 25.22%, while its annual performance rate touched -74.32%. The volatility ratio for the week stands at 6.27% while the volatility levels for the past 30 days are set at 8.87% for Plus Therapeutics, Inc.. The simple moving average for the period of the last 20 days is 22.08% for PSTV stocks with a simple moving average of 50.13% for the last 200 days.
PSTV Trading at 23.80% from the 50-Day Moving Average
After a stumble in the market that brought PSTV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.13% of loss for the given period.
Volatility was left at 8.87%, however, over the last 30 days, the volatility rate increased by 6.27%, as shares surge +6.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +32.47% upper at present.
During the last 5 trading sessions, PSTV rose by +15.91%, which changed the moving average for the period of 200-days by +47.83% in comparison to the 20-day moving average, which settled at $2.61. In addition, Plus Therapeutics, Inc. saw 1.67% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at PSTV starting from Lenk Robert P, who bought 3,000 shares at the price of $2.49 back on Aug 25. After this action, Lenk Robert P now owns 3,000 shares of Plus Therapeutics, Inc., valued at $7,465 using the latest closing price.
Petersen Greg, the Director of Plus Therapeutics, Inc., bought 10,000 shares at $2.80 during a trade that took place back on Aug 13, which means that Petersen Greg is holding 20,000 shares at $28,000 based on the most recent closing price.
Stock Fundamentals for PSTV
Current profitability levels for the company are sitting at:
- -52.26 for the present operating margin
The net margin for Plus Therapeutics, Inc. stands at -46.91. The total capital return value is set at -22.46, while invested capital returns managed to touch -93.39. Equity return is now at value -176.00, with -9.90 for asset returns.
Based on Plus Therapeutics, Inc. (PSTV), the company’s capital structure generated 1,032.16 points at debt to equity in total, while total debt to capital is 91.17. Total debt to assets is 51.54, with long-term debt to equity ratio resting at -1.97. Finally, the long-term debt to capital ratio is 55.69.
When we switch over and look at the enterprise to sales, we see a ratio of -0.33, with the company’s debt to enterprise value settled at -5.21. The receivables turnover for the company is 8.28 and the total asset turnover is 0.30. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.37.